Lisata Therapeutics to Present at the Investival Showcase USA
Rhea-AI Summary
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on therapies for advanced solid tumors and other serious diseases, announced that its President and CEO, David J. Mazzo, Ph.D., will present at the Investival Showcase USA. The event is scheduled for March 10-11, 2025, in Miami, Florida.
Dr. Mazzo's presentation will occur on March 11th at 11:30 a.m. Eastern Time. For more information about the conference and registration details, please click here.
Positive
- None.
Negative
- None.
BASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the Investival Showcase USA, taking place March 10-11, 2025 in Miami, Florida.
Dr. Mazzo’s presentation is scheduled for Tuesday, March 11th at 11:30 a.m. Eastern Time. For more information about the conference, including registration details, please click here.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the second quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.
Lisata Therapeutics Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com
This press release was published by a CLEAR® Verified individual.
FAQ
What is Lisata Therapeutics presenting at the Investival Showcase USA?
When is Lisata Therapeutics presenting at the Investival Showcase USA?
Where is the Investival Showcase USA taking place?
Who will present on behalf of Lisata Therapeutics at the Investival Showcase USA?
What is the focus of Lisata Therapeutics' presentation at the Investival Showcase USA?
When is the Investival Showcase USA scheduled?
